Melanoma Patients Matter – Report by Pharma

Melanoma Focus is pleased to share a new report, Melanoma Patients Matter, that has been published by the pharmaceutical company Bristol-Myers Squibb.

The NHS is committed to patients being at the heart of everything it does, and specifically ensuring patients are at the centre of any and all decisions made about their health. A diagnosis of melanoma often significantly changes a person’s life, so it is important that patients are informed, supported and empowered to make decisions that are right for them and give them the best opportunity to lead the life they want. Actively involving patients in their own care, treatment and support can lead to improved outcomes and experiences. 1

In order to understand how patients with melanoma are being involved in these decisions about their care and treatment, Melanoma Focus was invited by Bristol-Myers Squibb to share our experience and expertise in shaping the project and the resulting report, alongside the British Association of Skin Cancer Specialist Nurses (BASCSN), Melanoma Action and Support Scotland (MASScot) and Melanoma UK.

The views of patients across the UK with Stage 3 or Stage 4 melanoma were sought. The report found:

  • Only half of patients feel they completely understood their diagnosis and the nature of their illness, as explained by their clinician or Clinical Nurse Specialist (CNS) at diagnosis.
  • Only half of patients have found the information provided on treatment options to be ‘completely sufficient’ to make an informed choice.
  • Two-thirds of patients have not been given a personalised care plan and, of those who have been, 20 per cent report not having been involved in its creation.
  • Nine in ten patients have been given the name of a CNS to support them during treatment, and nine in ten patients have found it relatively easy to contact their CNS. However, the extent to which patients have found their CNS able to support them varies significantly.

With the aim of ensuring all patients have the opportunity to be involved in their treatment and care, the report sets out a series of recommendations focused on improving the experiences of patients with melanoma, including:

  • Clear, accessible information and support about a patient’s diagnosis and all treatment options must be provided as early as possible in a language and format appropriate for each patient to enable them to make informed decisions about their treatment and care. Patient decision aids must be made available to advanced melanoma patients, so they can explore the available treatment options with their healthcare professional and reach a decision on the treatment and care that is right for them.
  • There must be a focused effort to expand the melanoma CNS workforce across the UK to ensure that all patients have access to a named CNS, irrespective of where they live and where they receive treatment.
  • NHS England should ensure melanoma is an early adopter for the standardised roll out of care plans in cancer care.
  • NHS Scotland should consider introducing the concept of a personalised care plan to support melanoma patients’ input, understanding and expectations of their individual treatment and care.

This report, published by Bristol-Myers Squibb, is based on the results of a patient survey carried out in September 2018. We would like to thank all our supporters who responded to this survey for kindly sharing their insights and experiences of living with melanoma, and helping to identify key areas for improvement in care and support for patients with melanoma.

Follow this link to access a PDF copy of the report.

1 NHS England, Involving people in their own care. Available at: https://www.england.nhs.uk/ourwork/patient- participation/. Last accessed: January 2019







printer-friendly version